A patient had ureteral stents removed yesterday and now has hematuria and persistent flank/back pain; she cannot take ibuprofen (NSAIDs). What pain management options are appropriate, and should prednisone be used?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Post-Ureteral Stent Removal Pain Management

For this patient with persistent flank/back pain after stent removal who cannot take NSAIDs, use acetaminophen as first-line therapy (500-1000 mg every 6 hours, maximum 4000 mg/24 hours), and do NOT prescribe prednisone—it has no role in managing post-stent removal pain.

Why Prednisone is Not Appropriate

Prednisone is specifically indicated only for pain associated with inflammatory disorders or metastatic bone pain 1. Post-ureteral stent removal pain is not an inflammatory condition requiring corticosteroids 2. The FDA labeling for prednisone emphasizes significant risks including immunosuppression, infection risk, adrenal suppression, and multiple drug interactions 2—none of which are justified for routine post-procedural urological pain.

Recommended Pain Management Algorithm

First-Line: Acetaminophen

  • Dosing: 500-1000 mg every 6 hours (maximum 4000 mg/24 hours) 1, 3
  • Evidence: Moderate-certainty evidence shows acetaminophen reduces pain at 1-7 days post-procedure 3
  • Safety: Safe in patients who cannot take NSAIDs 4

Second-Line Options (if acetaminophen insufficient):

Consider opioids for moderate-to-severe pain 1:

  • Short-acting opioids (e.g., oxycodone 5 mg, hydrocodone/acetaminophen) for breakthrough pain
  • Prescribe minimal quantities (typically 5-10 tablets) 5, 6
  • Reserve for severe pain not controlled by acetaminophen alone

Alpha-blockers may help residual urinary symptoms 7, 8, 9, 10:

  • If she has persistent frequency, urgency, or bladder discomfort
  • Silodosin 8 mg or tamsulosin 0.4 mg daily
  • Most effective for stent-related lower urinary tract symptoms

Clinical Context for This Patient

Expected Symptoms Post-Stent Removal

Approximately 64% of patients experience symptoms after stent removal, with 60% reporting pain/discomfort 11. Key predictors of post-removal pain include:

  • Discomfort while stent was in place (strongest predictor) 11—your patient had pain during stent placement
  • Stone basket extraction procedures 11

The Hematuria Component

Blood around the kidneys and hematuria post-stent removal can occur from:

  • Mucosal irritation from the stent itself 8, 9
  • Trauma during removal
  • Underlying ureteral/renal pathology

Red flags requiring urgent evaluation 12:

  • Fever with flank pain (suggests infection/pyelonephritis)
  • Hemodynamic instability
  • Worsening pain despite analgesia
  • Signs of obstruction (anuria, severe hydronephrosis)

If she develops fever, altered mental status, or systemic symptoms, consider complicated UTI or urosepsis requiring antibiotics and possible imaging 12.

Why NSAIDs Would Have Been Ideal (But Are Contraindicated)

NSAIDs show the strongest evidence for post-procedural pain 3, 13:

  • Ibuprofen 400-600 mg every 6-8 hours would typically be first-line
  • Topical NSAIDs also effective 3
  • However, NSAIDs are absolutely contraindicated in patients with renal dysfunction, bleeding risk, or specific contraindications 14, 15

The FDA labeling explicitly warns about increased bleeding risk, renal toxicity, and GI complications with NSAIDs 15—particularly concerning in a patient with recent urological instrumentation and hematuria.

Common Pitfalls to Avoid

  1. Do not prescribe corticosteroids for routine post-stent pain—no evidence supports this and risks are substantial
  2. Avoid excessive opioid prescribing—most patients need ≤10 tablets 5, 6
  3. Do not ignore persistent symptoms beyond 1-2 weeks—may indicate retained stone, stricture, or infection 11
  4. Counsel on expected symptom duration—most resolve within 1-7 days 3, 11

Follow-Up Considerations

  • Symptoms persisting >1 week warrant re-evaluation 11
  • If pain worsens or fever develops, obtain urine culture and consider imaging 12
  • Hematuria should resolve within days; persistent gross hematuria requires investigation 16, 17

References

Guideline

pharmacological management of persistent pain in older persons.

Journal of the American Geriatrics Society (JAGS), 2009

Research

Ureteral Stent Discomfort and Its Management.

Current urology reports, 2018

Research

Ureteral Stent-Associated Pain: A Review.

Journal of endourology, 2016

Research

Symptoms after removal of ureteral stents.

Journal of endourology, 2015

Guideline

adult cancer pain.

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

Related Questions

What are the recommended pain management strategies for patients after ureteral stent placement?
What is the appropriate evaluation and management for burning dysuria after placement of bilateral urethral stents?
Is ureteral stent removal painful?
What is the likely cause and appropriate management of new flank pain and dysuria after endoscopic kidney stone removal with ureteral stent placement?
How should ureteral stent pain after ureteroscopic kidney stone removal be managed, and how long does the pain typically last?
What is the recommended evaluation and management for a 55-year-old woman presenting with heat intolerance and a new red rash on the chest and face?
In an adult patient, especially a woman with recurrent urinary tract infections, can a daily 500 mg cranberry oral tablet be combined with D‑mannose (500 mg twice daily or 1 g once daily) for UTI prophylaxis?
Why are my CBC results—white blood cell count 6.3 ×10⁹/L (low), hemoglobin 14.2 g/dL (high), mean corpuscular hemoglobin concentration 34.4 g/dL (high), neutrophil percentage 57.1 % (low), monocyte percentage 11.3 % (high), and eosinophil percentage 3.5 % (high)—slightly out of the normal reference range?
When should C‑peptide be measured to distinguish type 1 from type 2 diabetes, and what are the appropriate glucose and C‑peptide cut‑off values?
Which autoimmune and thyroid laboratory tests are indicated for a female patient with an intermittent red rash on the chest and face and heat intolerance?
Which angiotensin receptor blocker (ARB) is appropriate for a patient with an ejection fraction of 20%?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.